Research Progress of BRCA Gene and Diagnosis and Treatment of Ovarian Cancer

doi:10.12280/gjfckx.20200655

Abstract

Abstract:

Ovarian cancer is one of the most common malignant tumors threatening women′s life and health, and its mortality rate ranks first among gynecological tumors. Breast cancer susceptibility gene (BRCA) is an important cancer susceptibility gene. It takes part in the regulation of DNA damage repair, cell growth and apoptosis, and plays an indispensable role in maintaining cell genetic stability. The mutation of BRCA gene leads to the occurrence about 80% of genetic related ovarian cancer. Through the screening and detection of BRCA gene mutation, the risk of ovarian cancer can be effectively evaluated and predicted. The incidence of ovarian cancer can be reduced through intervention and accurate treatment can be guided. BRCA gene mutations have obvious ethnic and geographic specificity, and significantly affect the incidence rate and age of onset of ovarian cancer. It is an inevitable trend to carry out multi-center research, establish related databases, and formulate diagnostic and treatment standards that meet the Chinese people.

Key words: Ovarian neoplasms, Genes, BRCA1, Genes, BRCA2, Mutation, Homologous recombination, Molecular targeted therapy

CHEN Zhen-bo, MENG Yuan-guang. Research Progress of BRCA Gene and Diagnosis and Treatment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(2): 144-148.

References 30

[1]	Matsumoto K, Nishimura M, Onoe T, et al. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy[J]. Jpn J Clin Oncol, 2019,49(8):703-707. doi: 10.1093/jjco/hyz090. pmid: 31242303
[2]	Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms[J]. J Cell Mol Med, 2019,23(4):2303-2313. doi: 10.1111/jcmm.14133. doi: 10.1111/jcmm.14133 pmid: 30672100
[3]	Madariaga A, Lheureux S, Oza AM. Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations[J]. Cancers (Basel), 2019,11(3):416. doi: 10.3390/cancers11030416.
[4]	Manchana T, Phoolcharoen N, Tantbirojn P. BRCA mutation in high grade epithelial ovarian cancers[J]. Gynecol Oncol Rep, 2019,29:102-105. doi: 10.1016/j.gore.2019.07.007. doi: 10.1016/j.gore.2019.07.007 pmid: 31467961
[5]	Alemar B, Gregório C, Herzog J, et al. BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?[J]. PLoS One, 2017,12(11):e0187630. doi: 10.1371/journal.pone.0187630. doi: 10.1371/journal.pone.0187630 pmid: 29161300
[6]	Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C, et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico[J]. Cancer, 2015,121(3):372-378. doi: 10.1002/cncr.29058. doi: 10.1002/cncr.29058 pmid: 25236687
[7]	Gallardo-Rincón D, Álvarez-Gómez RM, Montes-Servín E, et al. Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients[J]. Transl Oncol, 2020,13(2):212-220. doi: 10.1016/j.tranon.2019.11.003. doi: 10.1016/j.tranon.2019.11.003 pmid: 31869745
[8]	Ruiz de Sabando A, Urrutia Lafuente E, García-Amigot F, et al. Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain)[J]. BMC Cancer, 2019,19(1):1145. doi: 10.1186/s12885-019-6277-x. doi: 10.1186/s12885-019-6277-x pmid: 31771539
[9]	Shi T, Wang P, Xie C, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer[J]. Int J Cancer, 2017,140(9):2051-2059. doi: 10.1002/ijc.30633. pmid: 28176296
[10]	Wu X, Wu L, Kong B, et al. The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients[J]. Int J Gynecol Cancer, 2017,27(8):1650-1657. doi: 10.1097/IGC.0000000000001065. doi: 10.1097/IGC.0000000000001065 pmid: 28692638
[11]	Bu H, Chen J, Li Q, et al. BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group[J]. J Obstet Gynaecol Res, 2019,45(11):2267-2274. doi: 10.1111/jog.14090. doi: 10.1111/jog.14090 pmid: 31411802
[12]	Jervis S, Song H, Lee A, et al. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants[J]. J Med Genet, 2014,51(2):108-113. doi: 10.1136/jmedgenet-2013-102015. pmid: 24277755
[13]	Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma[J]. Cancer, 2003,97(9):2187-2195. doi: 10.1002/cncr.11310. doi: 10.1002/cncr.11310 pmid: 12712470
[14]	Soegaard M, Kjaer SK, Cox M, et al. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark[J]. Clin Cancer Res, 2008,14(12):3761-3767. doi: 10.1158/1078-0432.CCR-07-4806. doi: 10.1158/1078-0432.CCR-07-4806 pmid: 18559594
[15]	Essel KG, Moore KN. Niraparib for the treatment of ovarian cancer[J]. Expert Rev Anticancer Ther, 2018,18(8):727-733. doi: 10.1080/14737140.2018.1490180. doi: 10.1080/14737140.2018.1490180 pmid: 29911447
[16]	Vos S, van Diest PJ, Moelans CB. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?[J]. Crit Rev Oncol Hematol, 2018,127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. doi: 10.1016/j.critrevonc.2018.05.008 pmid: 29891109
[17]	Varol U, Kucukzeybek Y, Alacacioglu A, et al. BRCA genes: BRCA 1 and BRCA 2[J]. J BUON, 2018,23(4):862-866. pmid: 30358186
[18]	Ellison G, Ahdesmäki M, Luke S, et al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice[J]. Hum Mutat, 2018,39(3):394-405. doi: 10.1002/humu.23375. doi: 10.1002/humu.23375 pmid: 29215764
[19]	Ong PY, Poon SL, Tan KT, et al. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens[J]. Gynecol Oncol, 2019,155(2):275-279. doi: 10.1016/j.ygyno.2019.08.027. doi: 10.1016/j.ygyno.2019.08.027 pmid: 31481248
[20]	Ellison G, Ahdesmäki M, Luke S, et al. An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice[J]. Hum Mutat, 2018,39(3):394-405. doi: 10.1002/humu.23375. doi: 10.1002/humu.23375 pmid: 29215764
[21]	Capoluongo E, Ellison G, López-Guerrero JA, et al. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients[J]. Semin Oncol, 2017,44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. doi: 10.1053/j.seminoncol.2017.08.004 pmid: 29248130
[22]	Zhong Q, Wagner U, Kurt H, et al. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing[J]. Pathol Res Pract, 2018,214(7):957-963. doi: 10.1016/j.prp.2018.05.020. doi: 10.1016/j.prp.2018.05.020 pmid: 29807778
[23]	da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, et al. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management[J]. Clinics (Sao Paulo), 2018,73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
[24]	皮如玉, 李佳蕊. PARP抑制剂在卵巢癌治疗中的研究进展[J]. 国际妇产科学杂志, 2016,43(5):515-518.
[25]	Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease[J]. Future Oncol, 2018,14(30):3101-3110. doi: 10.2217/fon-2018-0215. doi: 10.2217/fon-2018-0215 pmid: 30105925
[26]	钟姗姗, 狄文. Olaparib靶向治疗晚期卵巢癌的研究进展[J]. 国际妇产科学杂志, 2017,44(6):677-680,694. doi: 10.3969/j.issn.1674-1870.2017.06.018.
[27]	Slade D. PARP and PARG inhibitors in cancer treatment[J]. Genes Dev, 2020,34(5/6):360-394. doi: 10.1101/gad.334516.119.
[28]	Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer[J]. N Engl J Med, 2016,375(22):2154-2164. doi: 10.1056/NEJMoa1611310. doi: 10.1056/NEJMoa1611310 pmid: 27717299
[29]	Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. doi: 10.1016/S0140-6736(17)32440-6 pmid: 28916367
[30]	George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer[J]. Nat Rev Clin Oncol, 2017,14(5):284-296. doi: 10.1038/nrclinonc.2016.191. doi: 10.1038/nrclinonc.2016.191 pmid: 27958297